

AMENDMENTS TO THE CLAIMS:

This listing of claims replaces all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A combination product for delivery of a pharmacologically active substance, said combination product comprising:

(i) a positive oil in water emulsion wherein said emulsion comprises comprising, at the oil-water interface, at least one cationic lipid selected from the group consisting of a C₁₀-C₂₄ alkylamine, a C₁₀-C₂₄ alkanolamine and a cholesterol ester, at the oil-water interface, and

(ii) an antibody,

wherein:

said at least one cationic lipid compound is linked to said antibody by a heterobifunctional linker, and

the pharmacologically active substance is incorporated in the oil in water emulsion.

2. (currently amended) The combination product of claim 1, wherein said combination product has a positive zeta charge.

3. (cancelled)

4. (currently amended) The combination product of claim 3 2, wherein said at least one cationic lipid is stearylamine or oleylamine.

5. (currently amended) The combination product of claim 1, wherein said oil in water emulsion comprises ~~colloid~~ colloidal particles having an oily core surrounded by an interfacial film, wherein said interfacial film comprises said at least one cationic lipid, a nonionic surfactant and an anionic surfactant or anionic lipid, wherein said colloidal particles have a positive zeta potential.

6. (currently amended) The combination product of claim 5, wherein the pharmacologically active substance is incorporated in the oily core of the colloidal particles of said oil in water emulsion. ~~contains an active principle (drug).~~

7. (previously presented) The combination product of claim 1, wherein said antibody is a polyclonal antibody.

8. (currently amended) The combination product of claim 1, wherein said antibody is a monoclonal antibody selected

from the group consisting of ~~comprising~~ native forms, synthetic forms, chimeric forms and humanized forms.

9. (previously presented) The combination product of claim 1, wherein said antibody targets an antigen present at the surface of a pathological cell.

10. (currently amended) The combination product of claim 1, wherein said antibody targets a protein selected from the group consisting of ~~comprising~~ HER-2, H-ferritin, PSMA, mucins, MUC 1, CD 44 and retinal S-Ag.

11. (previously presented) The combination product of claim 1, wherein said antibody is AMB8LK antibody.

12. (currently amended) The combination product of claim 1, wherein said heterobiofunctional linker is ~~chosen from~~ N-1 stearyl-maleimide (SM), oleylmaleimide, succinimidyl, trans-4-(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC) and/or succinimidyl 3-(2-pyridyldithio)propionate (SPDP).

13. (currently amended) A method for producing a the combination product according to claim 1, said method comprising ~~the steps of:~~

a) optionally reducing an antibody in order to obtain free SH groups on its hinge region,

b) mixing a positive emulsion ~~wherein said emulsion comprises comprising~~ at least one cationic lipid presenting free NH₂ groups at its natural state, wherein said at least one cationic lipid is selected from the group consisting of a C₁₀-C₂₄ alkylamine, a C₁₀-C₂₄ alkanolamine, and a cholesterol ester, ~~at its natural state,~~ wherein said cationic lipid is linked to a heterobifunctional linker by said NH₂ groups, with the antibody presenting free SH groups in order to obtain said combination product.

14. (currently amended) The method of claim 13, wherein said positive emulsion in step b) is obtained by emulsion:

i linking a the heterobifunctional linker to a free NH₂ group naturally present on a said at least one cationic lipid that is used to obtain a positive emulsion, in order to obtain a modified ~~compound~~ cationic lipid, and

ii mixing said modified cationic lipid, ~~which at its natural state contains free NH₂ groups,~~ with water, oil and an emulsifying agent, in order to obtain a positive emulsion.

15. (currently amended) The method of claim 13, wherein said positive emulsion in step b) is obtained by:

~~±~~(i) mixing a said at least one cationic lipid, which at its natural state contains free NH₂ groups, with water, oil and an emulsifying agent in order to obtain a positive emulsion[[],];
and

~~±~~(ii) linking a said heterobifunctional linker to a free NH₂ group naturally present on said at least one cationic lipid, in order to obtain a modified cationic lipid within said positive emulsion.